Repros’ Proellex Is Poised To Enter Phase III – Again
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Telapristone was put on clinical hold due to liver toxicity, but the company’s pursuit of vaginal formulation and re-analysis of the initial oral studies allowed the oral program to resume.
You may also be interested in...
Keeping Track: Novel Orphan Drugs Amondys 45, Nulibry Clear US FDA; First-Line NSCLC Claim For Libtayo
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Complexity Has Benefits: Data Show Biologics, Targeted Agents Have Better Approval Prospects
Biologics have 9.1% likelihood of making it through the clinic to approval, compared to 5.7% for new molecular entities, according to an analysis of 10 years of Biomedtracker drug development data by BIO, Informa Pharma Intelligence and QLS.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: